ESC Premium Access

The SGLT2 inhibitor empagliflozin reduces mortality in experimental pulmonary hypertension

Congress Presentation

About the speaker

Professor Subodh Verma

St. Michael's Hospital, Toronto (Canada)
26 presentations
0 follower

4 more presentations in this session

State of the Art - Metabolic aspects of vascular disease

Speaker: Professor M. Federici (Rome, IT)


Role of the gut microbiome for the cholesterol lowering effect of atorvastatin

Speaker: Miss F. Zimmermann (Berlin, DE)


Identification of celastramycin as a novel therapeutic agent for pulmonary arterial hypertension -high-throughput screening of 5,562 compounds-

Speaker: Doctor R. Kurosawa (Sendai, JP)


Microparticles from vascular endothelial growth factor pathway inhibitor-treated cancer patients mediate endothelial cell injury

Speaker: Professor R. Touyz (Montreal, CA)


Access the full session

Novel pharmacological targets in vascular disease

Speakers: Professor S. Verma, Professor M. Federici, Miss F. Zimmermann, Doctor R. Kurosawa, Professor R. Touyz

About the event


ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb